|  |
| --- |
| * **Principle** – alert registered stakeholders to the publication of a decision to update a guideline * **Links to include** – web page for stakeholder registration * **Attachments to include** – none * **Info to include** – Guideline title; further info contact name and email address |

**Email Address you want replies to go to**

[Surveillance@nice.org.uk](mailto:Surveillance@nice.org.uk)

**CC:**

[Surveillance@nice.org.uk](mailto:Surveillance@nice.org.uk),

**Email subject:**

Update decision: the NICE guideline on NG5 Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes

**Email:**

Dear Colleague

**RE: NICE guideline on NG5 Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes**

I am writing to let you know that, after considering the evidence and consulting with experts, we have decided not to update this guideline. Information about the decision has been published on our [website](http://www.nice.org.uk/guidance/NG5).

We would like to thank you for your continued support and your interest in NICE guidelines.

If you have any queries about the update decision, please contact me at [surveillance@nice.org.uk](mailto:surveillance@nice.org.uk)

Kind regards,

Surveillance Team

Surveillance Reviews  
NICE Centre for Guidelines  
National Institute for Health and Care Excellence Level 1A | City Tower | Piccadilly Plaza | Manchester M1 4BT | United Kingdom  
[www.nice.org.uk](http://www.nice.org.uk)